SGA
VRTX icon

Strategic Global Advisors’s Vertex Pharmaceuticals VRTX Stock Holding History

Strategic Global Advisors’s Portfolio VRTX Stock Details VRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		– Sell
-7,708
Closed -$2.71M – 170
2023
Q2 		$2.71M Sell
7,708
-450
-6% -$152K 0.42% 79
2023
Q1 		$2.57M Sell
8,158
-677
-8% -$203K 0.41% 79
2022
Q4 		$2.55M Sell
8,835
-141
-2% -$43K 0.41% 83
2022
Q3 		$2.6M Sell
8,976
-253
-3% -$72.8K 0.43% 79
2022
Q2 		$2.6M Buy
9,229
+990
+12% +$265K 0.4% 86
2022
Q1 		$2.15M Buy
8,239
+292
+4% +$69.3K 0.31% 90
2021
Q4 		$1.75M Buy
7,947
+622
+8% +$121K 0.23% 108
2021
Q3 		$1.33M Buy
7,325
+1,532
+26% +$299K 0.19% 117
2021
Q2 		$1.17M Sell
5,793
-633
-10% -$132K 0.21% 125
2021
Q1 		$1.38M Sell
6,426
-361
-5% -$79.3K 0.25% 113
2020
Q4 		$1.6M Sell
6,787
-157
-2% -$36K 0.28% 104
2020
Q3 		$1.89M Buy
6,944
+2,512
+57% +$693K 0.36% 77
2020
Q2 		$1.29M Buy
4,432
+1,192
+37% +$323K 0.28% 95
2020
Q1 		$771K Buy
+3,240
New +$743K 0.2% 102

Other funds holding VRTX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $302B AUM 26.44% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Strategic Global Advisors's VRTX Position: Q3 2023 in Review

Strategic Global Advisors sold out of Vertex Pharmaceuticals (VRTX) in Q3 2023, closing a stake of 7,708 shares — an estimated $2.71M sold.

Strategic Global Advisors first reported a position in VRTX in Q1 2020 and held it in 14 quarters. The position peaked at $2.71M in Q2 2023. 1,277 funds tracked by Wall St. Rank hold VRTX as of Q3 2023.

  • Strategic Global Advisors reported no remaining Vertex Pharmaceuticals position as of Q3 2023 after selling out during the quarter.
  • Strategic Global Advisors sold 7,708 Vertex Pharmaceuticals shares in Q3 2023, an estimated $2.71M.
  • Strategic Global Advisors first reported a position in Vertex Pharmaceuticals in Q1 2020 and held it in 14 quarters.
  • Strategic Global Advisors's Vertex Pharmaceuticals position peaked at $2.71M in Q2 2023.
  • 1,277 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q3 2023.

Based on Strategic Global Advisors's 13F filing for Q3 2023, filed 14 Nov 2023.